Description
This page contains brief details about the drug rituximab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Rituximab is an immunomodulatory monoclonal antibody (a protein that attaches to a specific target) that was approved for its medical use on 26th November 1997.
Mechanism of Action of Rituximab
Rituximab Injection is a biological agent that belongs to the category of medications called monoclonal antibodies. It specifically targets and binds to the CD20 receptors, resulting in a significant decrease in the inflammatory mediators. The medicine inhibits the availability of B cells by depleting them and eventually stops the growth and multiplication of cancer cells.
Uses of Rituximab
Rituximab Injection has been developed to treat non-Hodgkin’s lymphoma, mature B-cell acute leukemia, chronic lymphocytic leukemia, granulomatosis, rheumatoid arthritis, and pemphigus vulgaris in patients who have not responded adequately to other treatments.
Rituximab Dosage available
Rituximab is available as a single-use vial of injection intended for administration as an intravenous infusion. It is available in doses of 100mg and 500mg. The usual recommended starting dose is 375mg/m2. Your doctor will decide the dose, dosage, and duration of the treatment based on your medical condition.
